38695-92-0

Usage

Uses

Used in Pharmaceutical Industry:
1H-pyrazol-5-ol, 3-methyl-1-(2-pyridinyl)is used as a building block for the synthesis of biologically active molecules due to its unique chemical structure and potential medicinal properties. It serves as a crucial component in the development of new pharmaceutical drugs and compounds, contributing to the advancement of medical treatments and therapies.
Used in Research and Development:
1H-pyrazol-5-ol, 3-methyl-1-(2-pyridinyl)is utilized in various research and development processes to explore its potential applications and properties. It is studied for its anti-inflammatory and analgesic effects, which could lead to the discovery of new treatments for pain and inflammation-related conditions. 1H-pyrazol-5-ol, 3-methyl-1-(2-pyridinyl)-'s versatility and reactivity in chemical reactions make it a valuable tool for scientists and researchers in the field of medicinal chemistry.

Upstream product

• 4930-98-7 pyrid-2-ylhydrazine 
• 141-97-9 ethyl acetoacetate 
• 1207678-75-8 2-(5-isopropoxy-3-methyl-1H-pyrazol-1-yl)pyridine 
• 123-54-6 acetylacetone 
• 109-09-1 2-chloropyridine 

Downstream Products

• 1334782-08-9 (4Z)-4-[amino(phenyl)methylene]-5-methyl-2-(2-pyridinyl)-2,4-dihydro-3H-pyrazol-3-one 
• 1334782-03-4 [5-hydroxy-3-methyl-1-(2-pyridinyl)-1H-pyrazol-4-yl](phenyl)methanone 
• 153231-88-0 4,4'-(phenylmethylene)bis[3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-ol] 
• 1334782-05-6 3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-yl benzoate 
• 1354790-50-3 5-methyl-3-oxo-2-(pyridin-2-yl)-N-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrazole-4-carboxamide 

Relevant academic research and scientific papers

4-Substituted quinoline derivatives and preparation methods and applications thereof

The present invention provides a 4-substituted quinoline derivative and preparation method and application thereof, in particular, the present invention relates to a compound shown in formula (I), a method for preparing a compound shown in formula (I), an

Arene-ruthenium(II) complexes with pyrazole-based ligands bearing a pyridine moiety: Synthesis, structure, DFT calculations, and cytotoxicity

Two pyrazole-based ligands bearing a pyridine moiety, 3-methyl-1-(pyridin-2-yl)-5-pyrazolone (HLpy), and 3-methyl-1-(pyridin-2-yl)-4-trifluoroacetyl-5-pyrazolone (HQpy,CF3), were prepared and fully characterized in the solid-state and the tautomerism of both ligands in solution was also rationalized by using Density Functional Theory. Neutral ruthenium(II) arene complexes of composition [Ru(arene)(Lpy)Cl] and [Ru(arene)(Qpy,CF3)Cl] [arene = p-cymene (cym) or hexamethylbenzene (hmb)]) were synthesized and characterized by IR, 1H, 13C, 15N and 19F NMR spectroscopy, elemental analysis and ESI mass spectrometry. The structures of complexes [Ru(hmb)(Lpy)Cl] and [Ru(hmb)(Qpy,CF3)Cl] were determined by X-ray crystallography, showing κ2-N,N’-coordination not only for Lpy but also for Qpy,CF3 ligand. DFT studies confirm that κ2O,O’-coordination, generally observed in metal complexes with 4-acyl-5-pyrazolone ligands, is not favored in this case. The cytotoxicity of ligands and complexes was evaluated against human ovarian carcinoma cells (A2780 and A2780cisR, cisplatin sensitive and cisplatin-resistant, respectively), and non-tumorous human embryonic kidney SV40 transformed (HEK293T) cells to reveal essentially equivalent activity in the cisplatin sensitive and cisplatin-resistant ovarian carcinoma cells.

Pyrazolyl-pyrimidones inhibit the function of human solute carrier protein SLC11A2 (hDMT1) by metal chelation

Solute carrier proteins (SLCs) control fluxes of ions and molecules across biological membranes and represent an emerging class of drug targets. SLC11A2 (hDMT1) mediates intestinal iron uptake and its inhibition might be used to treat iron overload diseases such as hereditary hemochromatosis. Here we report a micromolar (IC50 = 1.1 μM) pyrazolyl-pyrimidone inhibitor of radiolabeled iron uptake in hDMT1 overexpressing HEK293 cells acting by a non-competitive mechanism, which however does not affect the electrophysiological properties of the transporter. Isothermal titration calorimetry, competition with calcein, induced precipitation of radioactive iron and cross inhibition of the unrelated iron transporter SLC39A8 (hZIP8) indicate that inhibition is mediated by metal chelation. Mapping the chemical space of thousands of pyrazolo-pyrimidones and similar 2,2′-diazabiaryls in ChEMBL suggests that their reported activities might partly reflect metal chelation. Such metal chelating groups are not listed in pan-assay interference compounds (PAINS) but should be checked when addressing SLCs.

Chemoselective Synthesis of 5-Alkylamino-1H-pyrazole-4-carbaldehydes by Cesium- and Copper-Mediated Amination

Microwave-assisted synthesis of new 5-alkylamino-pyrazole-4-carbaldehydes was performed efficiently, with yields up to 99 and short reaction times. Nucleophilic substitution of primary alkylamines with activated 5-chloro-1-(2-pyridyl)pyrazole-4-carbaldehyde was mediated by the "cesium effect". The amination of deactivated 1-aryl-5-chloropyrazole-4-carbaldehydes was also assisted by the cesium ion and catalyzed by copper(I). Hereby is described an efficient protocol for the chemoselective synthesis of new 5-alkylaminopyrazole-4-carbaldehydes from 5-chloropyrazole-4-carbaldehydes and primary alkylamines in one step to give products with good to excellent yields and short reaction times. Unexpectedly, under these reaction conditions the corresponding alkylimine formation was not observed.

Alkoxypyrazoles and the process for their preparation

The present invention relates to a alkoxypyrazoles preparation process, and new alkoxypyrazole compounds.

SPIROCHROMANON DERIVATIVES

The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-b]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.